Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
August 06, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviralagents progresses – ...
Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal
August 04, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
– Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication – – Cocrystal is currently further conducting preclinical studies of these coronavirus...
Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
May 14, 2020 07:05 ET
|
Cocrystal Pharma, Inc.
- Company has sufficient capital to advance pipeline and fund operations through 2021 - BOTHELL, WA, May 14, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc (NASDAQ: COCP), (“Cocrystal” or the...
Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action
April 22, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
- Expanded license agreement with KSURF further broadens and advances Cocrystal’s COVID-19 program - - Small molecule therapeutic inhibitors against coronaviruses included in agreement have...
Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020
March 30, 2020 06:05 ET
|
Cocrystal Pharma, Inc.
Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration with Merck to discover...
Cocrystal Pharma Announces Plans to Advance Coronavirus Program
March 06, 2020 16:01 ET
|
Cocrystal Pharma, Inc.
Company has immediately initiated Coronavirus programLeveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Strong financial position bolsters Company’s...